Brooks Laboratories Limited (NSE:BROOKS)

Market Cap	1.98B
Revenue (ttm)	927.94M
Net Income (ttm)	139.72M
Shares Out	29.46M
EPS (ttm)	4.92
PE Ratio	13.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,361
Average Volume	84,251
Open	67.80
Previous Close	67.06
Day's Range	65.02 - 67.80
52-Week Range	64.01 - 173.65
Beta	0.58
RSI	26.59
Earnings Date	Feb 12, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 323
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BROOKS

Financial Performance

In 2024, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2023.